04.25.25 -- Climbing The Blockchain Ladder To Optimize Clinical Supply Forecasting

Five years post-COVID, global vaccine development is experiencing a surge of innovation. Let's examine seven key trends shaping the future of vaccine manufacturing and accessibility in 2025.

Explore how early adoption of fully compendial, cGMP raw materials can provide a return on investment by reducing steps in your process and potential yield losses and avoiding lost production time. 

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models and seeking more resilient, forward-looking strategies.

High-quality process development aims to maintain a consistent process from toxicology through to GMP production runs, and can be aided by a capable, adaptable CDMO.

Could a new approach to operator training help minimize batch loss? Learn how blended learning can enhance training effectiveness and engagement, reducing human error in your production line.

Uncover a comprehensive framework for conducting robust comparability studies that ensure biosimilars meet stringent standards for safety, efficacy, and quality.

With these four steps to successful biologic process development, it is possible to mitigate risk, manufacture a high-quality product, and increase the efficiency of your timeline to patients.

Increased investment in allogeneic therapies and process-level advancements to achieve commercial scale are paving the way for streamlined, standardized cell therapy development and manufacturing.

Allogeneic cell therapies offer incredible promise, but scaling up PSC manufacturing presents unique challenges. Explore these hurdles along with solutions for consistent, high-quality production.

Stirred-tank bioreactors have emerged in recent years as the optimal platform to optimize (stem) cell culturing raising their potential in the cell and gene therapy industry.

Examine how the Project Ready program was leveraged to streamline validation processes for a CDMO, resulting in a 25% reduction in budget and faster project completion.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

The heterogeneity of a biologic product has implications for the final therapy's safety and efficacy. Explore challenges associated with charged variants, including mAbs and fusion proteins.

Achieve automated and reliable AAV capsid analysis with the right mass photometer. Review studies that showcase an automated mass photometer designed for AAV characterization.

By founding their latest venture, Abpro, Ian and Eugene Chan are using their synergistic skillsets in business and medicine to rapidly generate antibodies that treat cancer and autoimmune diseases.

Discover how knowledge of microbial processes and process characterization understanding can be used to design targeted BLA programs while managing risks.